➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Express Scripts
Mallinckrodt
Johnson and Johnson
Colorcon
Medtronic

Last Updated: August 6, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR KYMRIAH

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for KYMRIAH

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03628053 ↗ Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia Not yet recruiting Novartis Pharmaceuticals Phase 3 2019-01-17 This trial aims to compare the benefits and risks of tisagenlecleucel to blinatumomab or inotuzumab in adult patients with relapsed or refractory ALL. This trial investigates tisagenlecleucel as an additional treatment option for this patient population with high unmet medical need.
NCT03642626 ↗ MT2017-45 :CAR-T Cell Therapy for Heme Malignancies Not yet recruiting Masonic Cancer Center, University of Minnesota Phase 2 2018-12-01 This is a phase II study of FDA-approved CAR-T products for patients with hematologic malignancies. Patients will be assigned to Arm A and B based on age and diagnosis. Overall remission rate, safety events and other endpoints will be calculated for Arm A and B separately.
NCT04161118 ↗ Phase II Trial of TisaGenlecleucel (Kymriah®) in Elderly Patients With First-Relapsed or Primary Refractory Agressive B-cell Non-Hodgkin Lymphoma Not yet recruiting Novartis Phase 2 2020-08-01 A phase II trial of TisaGenlecleucel (Kymriah®) in Elderly Patients with First-Relapsed or Primary Refractory Agressive B-cell Non-Hodgkin Lymphoma
NCT04161118 ↗ Phase II Trial of TisaGenlecleucel (Kymriah®) in Elderly Patients With First-Relapsed or Primary Refractory Agressive B-cell Non-Hodgkin Lymphoma Not yet recruiting University of Cologne Phase 2 2020-08-01 A phase II trial of TisaGenlecleucel (Kymriah®) in Elderly Patients with First-Relapsed or Primary Refractory Agressive B-cell Non-Hodgkin Lymphoma
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for KYMRIAH

Condition Name

Condition Name for KYMRIAH
Intervention Trials
Acute Lymphoblastic Leukemia 2
High-grade B-cell Lymphoma 1
DLBCL Arising From Follicular Lymphoma 1
DLBCL 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for KYMRIAH
Intervention Trials
Lymphoma, B-Cell 4
Lymphoma 3
Lymphoma, Large B-Cell, Diffuse 2
Precursor Cell Lymphoblastic Leukemia-Lymphoma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for KYMRIAH

Trials by Country

Trials by Country for KYMRIAH
Location Trials
United States 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for KYMRIAH
Location Trials
Georgia 1
Minnesota 1
Illinois 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for KYMRIAH

Clinical Trial Phase

Clinical Trial Phase for KYMRIAH
Clinical Trial Phase Trials
Phase 3 1
Phase 2 2
Phase 1/Phase 2 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for KYMRIAH
Clinical Trial Phase Trials
Not yet recruiting 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for KYMRIAH

Sponsor Name

Sponsor Name for KYMRIAH
Sponsor Trials
Novartis 2
Masonic Cancer Center, University of Minnesota 2
Novartis Pharmaceuticals 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for KYMRIAH
Sponsor Trials
Other 5
Industry 3
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
Baxter
Dow
Merck
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.